Neisvac-C1

N. meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid A, the active ingredient in Neisvac-C1, is a conjugate vaccine presented as a sterile powder for intramuscular use. It induces immunity against invasive disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents and adults.

GNH USA supplies Neisvac-C1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac-C1 is a conjugate vaccine targeting the meningococcal disease pathway caused by Neisseria meningitidis serogroup C. - Infants and young children: provides active immunity against serogroup C meningococcal disease. - Adolescents and adults: maintains protective antibody levels to prevent invasive disease. - Travelers to endemic regions: reduces risk of acquiring Neisseria meningitidis serogroup C infection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema that resolves within a few days. - Fever: transient low‑grade temperature elevation. - Headache or fatigue: mild systemic symptoms post‑vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - Seizures: uncommon occurrence, especially in febrile children. - Severe local reaction: extensive necrosis or abscess formation at injection site. - Immune‑mediated thrombocytopenia: rare drop in platelet count.

Precautions should be observed when administering Neisvac-C1. - Pregnancy: safety not established; vaccinate only if clearly needed. - Breastfeeding: consider risk‑benefit balance before use. - Immunocompromised patients: may exhibit reduced antibody response. - History of severe allergic reaction to tetanus toxoid or any vaccine component: avoid administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential interactions with other medicines or vaccines are limited. Major Interactions (Avoid): - Severe allergic reaction to tetanus toxoid: contraindicates use of Neisvac-C1. - Simultaneous injection of another vaccine containing tetanus toxoid at the same site: may increase risk of local adverse reactions.

Moderate Interactions (Monitor Closely): - Concurrent administration of immunoglobulins: may diminish vaccine efficacy. - Use of immunosuppressive therapy: may reduce immune response to the vaccine.